>>> US Gapping up

Gapping up
In reaction to earnings/guidance:
  • YETI +13.5%, APP +13.4%, BLBD +11.9%, BMBL +11.5% (also increases buyback authorization to $450 mln), EMBC +11.4%, WRBY +10.6%, VITL +10.3%, EQIX +9.8%, MGNI +9.7%, SITM +9.4%, ASLE +9.3%, HUBS +8.8%, BIGC +8.4%, HPK +8.1%, FVRR +7.3%, SN +7.3%, ESTA +7.2%, CAMT +7.2%, EGHT +6.8%, BLND +6.8%, KVYO +6.8%, JXN +6.4%, STKL +6.2%, STN +6%, SPB +5.9%, RCUS +5.8%, XMTR +5.8%, STE +5.7% (also announces restructuring), HIMX +5.7%, COMM +5.7%, SBGI +5.6%, MKSI +5.4%, COOK +5.3%, HOOD +5.1%, RUN +4.9%, PETQ +4.8%, INST +4.8%, PRVA +4.8%, ARHS +4.7%, PGY +4.7%, LNW +4.6%, CAKE +4.5%, TSEM +4.3%, CARS +4%, MRSN +3.8%, MRVI +3.6%, CWEN +3.6%, NTLA +3.5%, PRMW +3.4%, ORA +3.3%, PRIM +3.2%, HBI +3.1%, ACDC +3%, PLTK +2.6%, NVMI +2.6%, DNUT +2.5%, AHH +2.4%, MNKD +2.3%, NUS +2.2%, FLNC +2.1%, HLIO +2.1%, KNTK +2%, ZD +2%, RVMD +1.8%, WES +1.7%, NTR +1.4%, USFD +1.4%, TTD +1.3%, IONQ +1.3%, MFC +1.3%, HL +1.2%, ATO +1.2% (also increases dividend), CRL +1.2%, NXST +1.2%, FSK +1.1%, TTEC +1.1%, NVEE +1.1%, CENT +1.1%, TNK +1.1%, EXK +1.1%, VZIO +1%
Other news:
  • XFOR +10.6% (has completed the sale of its Rare Pediatric Disease Priority Review Voucher to an undisclosed purchaser for $105 mln and that it has drawn an additional tranche of $20 mln under its existing loan facility with Hercules Capital)
  • CANF +8.9% (announces that the U.S. FDA has granted Investigational New Drug clearance for Namodenoson, for the treatment of patients with metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis, for the Company's ongoing Phase IIb clinical study)
  • HG +7.3% (to repurchase 9,124,729 shares owned by Blackstone)
  • CRSR +3.7% (seeking to acquire Fanatec brand)
  • PBPB +2.5% (files $75 mln mixed shelf securities offering)
  • TPL +1.2% (files mixed shelf securities offering)
Analyst comments:
  • CAKE +4.5% (upgraded to Outperform from Mkt Perform at Raymond James)
  • EDIT +4% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
  • EVGO +2.9% (upgraded to Overweight from Neutral at Cantor Fitzgerald )
  • WTTR +2.7% (upgraded to Buy from Neutral at Citigroup)
  • FOXA +1.7% (upgraded to Buy from Neutral at BofA Securities)
  • SHOP +1% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities; upgraded to Neutral from Underweight at Piper Sandler)